Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCINTRA: Biodistribution and Efficacy of Radiolabeled Cimzia in RA and SpA
NCT01590966Phase 3Completed
- Sponsor
- Ghent University Hospital
- Start
- Oct 2012
- Primary completion
- Mar 2019
- Modality
- Antibody Fragments, Polymer-based Nanoparticles
- Countries
- 1
01
Overview
A Phase 3 trial of certolizumab pegol in rheumatoid arthritis (RA), axial spondyloarthritis (axSpA), peripheral spondyloarthritis (pSpA), ankylosing spondylitis (AS), sponsored by Ghent University Hospital. Started Oct 2012; status: completed.
02
Drugs
certolizumab pegol
03
Conditions
rheumatoid arthritis (RA)axial spondyloarthritis (axSpA)peripheral spondyloarthritis (pSpA)ankylosing spondylitis (AS)
Beyond the preview
Go deeper on NCT01590966.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01590966.